February 7th 2025
GLP-1 RA use was linked to a reduced risk of alcohol-associated liver disease, lower rates of hepatic decompensation, and improved survival.
February 6th 2025
Findings suggest the value of genotyping and histological assessment for guiding HCC screening decisions in patients with chronic HBV.
February 5th 2025
Findings from the LIVERHOPE trial suggest adding simvastatin and rifaximin to standard therapy does not reduce ACLF occurrence.
February 3rd 2025
This month in review spotlights HCPLive’s coverage of hepatic pipeline news and recent research about MASLD, liver transplant, and alcohol in liver disease.
February 1st 2025
Our top 5 headlines include approvals for a non-opioid pain reliever, the latest indication for semaglutide, positive phase 2 data in MASH, and more.